Clinical Trial Update: HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma [Phase 1]

View source ↗

Summary

Phase 1 trial update for HERV-E TCR-transduced autologous T cells in metastatic clear cell renal cell carcinoma, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• HERV-E TCR-transduced autologous T cells

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Kidney Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-12-03